Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study on the Safety and Tolerability of a CDK4 / 6 Inhibitor and a MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors

NCT04615312 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT04615312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04615312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study on the Safety and Tolerability of a CDK4 / 6 Inhibitor and a MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors
Lead sponsor
Henan Cancer Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
November 14, 2020
Completion date
August 30, 2022
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

digestive system tumors